Brazil · Delayed Price · Currency is BRL Ouro Fino Saúde Animal Participações Earnings Call Transcripts
Fiscal Year 2026
-
Q2 saw nearly 20% revenue growth and 26.5% EBITDA growth, led by new product launches and strong livestock and international performance. Pet segment growth was modest due to macroeconomic pressures, but outlook for the second half remains positive.
-
Adjusted for the absence of the Foot-and-Mouth Disease campaign, revenue and EBITDA grew strongly year-over-year, with significant margin improvements and robust cash flow. New product launches and cost discipline supported growth in both production animals and pets, while international operations faced mixed results.
-
Q3 2024 saw double-digit revenue and EBITDA growth, margin expansion, and strong cash flow, driven by new product launches and operational efficiency. Despite logistics and climate challenges, both production animal and pet segments delivered robust results, with a positive outlook for 2025.
-
Q4 2025 saw revenue up 23.2% and net income up 17.2% year-over-year, driven by strong product launches, reduced expenses, and international expansion. Guidance for 2026 targets continued growth above prior year, with a focus on Latin America and biologics.
-
Q1 2026 saw over 30% revenue growth, margin expansion, and strong cash generation, driven by new product launches and operational efficiency. Production and companion animal segments both grew, with international operations gaining relevance. Dividend payouts increased alongside continued investment.
-
Revenue grew 14% year-over-year to BRL 1 billion, with all business units contributing and EBITDA margin rising to 21.6%. Seven new products were launched, cash generation was strong, and leverage was reduced, supporting continued investment and international expansion.
-
Revenue and EBITDA grew 26% and 30% year-over-year, driven by innovative product launches and strong segment performance. Robust liquidity, long-term debt structure, and continued R&D investment support future growth.
-
Q1 2025 saw 6.3% revenue growth and a gross margin of 48.5%, with strong gains in pet and international segments. New product launches and robust cash flow support a positive outlook, though higher SG&A and R&D investments may pressure margins.
-
Net revenue grew over 30% year-over-year, with strong gains in both production and companion animal segments. EBITDA and net income margins expanded, supported by innovation and international growth, despite some one-time impacts from project suspensions.